This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).
This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.
Summary of the CAPTIVATE platform which will be a twitter spaces discussion
This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?